These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 15867256)

  • 1. Antiangiogenic properties of gold nanoparticles.
    Mukherjee P; Bhattacharya R; Wang P; Wang L; Basu S; Nagy JA; Atala A; Mukhopadhyay D; Soker S
    Clin Cancer Res; 2005 May; 11(9):3530-4. PubMed ID: 15867256
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of cloned tumstatin-related and angiogenesis-inhibitory peptides on proliferation and apoptosis of endothelial cells.
    Zhang GM; Zhang YM; Fu SB; Liu XH; Fu X; Yu Y; Zhang ZY
    Chin Med J (Engl); 2008 Nov; 121(22):2324-30. PubMed ID: 19080341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-flt1 peptide, a vascular endothelial growth factor receptor 1-specific hexapeptide, inhibits tumor growth and metastasis.
    Bae DG; Kim TD; Li G; Yoon WH; Chae CB
    Clin Cancer Res; 2005 Apr; 11(7):2651-61. PubMed ID: 15814646
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Nanogold inhibits angiogenesis and growth of liver cancer: experiment with mice].
    Pan YL; Qiu SY; Qin L; Cai JY; Sun JS
    Zhonghua Yi Xue Za Zhi; 2009 Mar; 89(12):800-4. PubMed ID: 19595116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
    Lane HA; Wood JM; McSheehy PM; Allegrini PR; Boulay A; Brueggen J; Littlewood-Evans A; Maira SM; Martiny-Baron G; Schnell CR; Sini P; O'Reilly T
    Clin Cancer Res; 2009 Mar; 15(5):1612-22. PubMed ID: 19223496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.
    Qian F; Engst S; Yamaguchi K; Yu P; Won KA; Mock L; Lou T; Tan J; Li C; Tam D; Lougheed J; Yakes FM; Bentzien F; Xu W; Zaks T; Wooster R; Greshock J; Joly AH
    Cancer Res; 2009 Oct; 69(20):8009-16. PubMed ID: 19808973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1.
    Starzec A; Vassy R; Martin A; Lecouvey M; Di Benedetto M; Crépin M; Perret GY
    Life Sci; 2006 Nov; 79(25):2370-81. PubMed ID: 16959272
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ganglioside GM3 inhibits VEGF/VEGFR-2-mediated angiogenesis: direct interaction of GM3 with VEGFR-2.
    Chung TW; Kim SJ; Choi HJ; Kim KJ; Kim MJ; Kim SH; Lee HJ; Ko JH; Lee YC; Suzuki A; Kim CH
    Glycobiology; 2009 Mar; 19(3):229-39. PubMed ID: 18974200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The transforming growth factor-beta family members bone morphogenetic protein-2 and macrophage inhibitory cytokine-1 as mediators of the antiangiogenic activity of N-(4-hydroxyphenyl)retinamide.
    Ferrari N; Pfeffer U; Dell'Eva R; Ambrosini C; Noonan DM; Albini A
    Clin Cancer Res; 2005 Jun; 11(12):4610-9. PubMed ID: 15958647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel low molecular weight VEGF receptor-binding antagonist, VGA1102, inhibits the function of VEGF and in vivo tumor growth.
    Ueda Y; Yamagishi T; Samata K; Ikeya H; Hirayama N; Okazaki T; Nishihara S; Arai K; Yamaguchi S; Shibuya M; Nakaike S; Tanaka M
    Cancer Chemother Pharmacol; 2004 Jul; 54(1):16-24. PubMed ID: 15064856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of endothelial cell differentiation and proinflammatory cytokine production during angiogenesis by allyl isothiocyanate and phenyl isothiocyanate.
    Thejass P; Kuttan G
    Integr Cancer Ther; 2007 Dec; 6(4):389-99. PubMed ID: 18048887
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decursin and decursinol angelate inhibit VEGF-induced angiogenesis via suppression of the VEGFR-2-signaling pathway.
    Jung MH; Lee SH; Ahn EM; Lee YM
    Carcinogenesis; 2009 Apr; 30(4):655-61. PubMed ID: 19228635
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
    Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
    Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts.
    Polverino A; Coxon A; Starnes C; Diaz Z; DeMelfi T; Wang L; Bready J; Estrada J; Cattley R; Kaufman S; Chen D; Gan Y; Kumar G; Meyer J; Neervannan S; Alva G; Talvenheimo J; Montestruque S; Tasker A; Patel V; Radinsky R; Kendall R
    Cancer Res; 2006 Sep; 66(17):8715-21. PubMed ID: 16951187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiangiogenic activity of beta-eudesmol in vitro and in vivo.
    Tsuneki H; Ma EL; Kobayashi S; Sekizaki N; Maekawa K; Sasaoka T; Wang MW; Kimura I
    Eur J Pharmacol; 2005 Apr; 512(2-3):105-15. PubMed ID: 15840394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherin.
    Lamszus K; Brockmann MA; Eckerich C; Bohlen P; May C; Mangold U; Fillbrandt R; Westphal M
    Clin Cancer Res; 2005 Jul; 11(13):4934-40. PubMed ID: 16000592
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel 2,3-dihydro-1,4-benzoxazines as potent and orally bioavailable inhibitors of tumor-driven angiogenesis.
    La DS; Belzile J; Bready JV; Coxon A; DeMelfi T; Doerr N; Estrada J; Flynn JC; Flynn SR; Graceffa RF; Harriman SP; Larrow JF; Long AM; Martin MW; Morrison MJ; Patel VF; Roveto PM; Wang L; Weiss MM; Whittington DA; Teffera Y; Zhao Z; Polverino AJ; Harmange JC
    J Med Chem; 2008 Mar; 51(6):1695-705. PubMed ID: 18311900
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization.
    LaMontagne K; Littlewood-Evans A; Schnell C; O'Reilly T; Wyder L; Sanchez T; Probst B; Butler J; Wood A; Liau G; Billy E; Theuer A; Hla T; Wood J
    Cancer Res; 2006 Jan; 66(1):221-31. PubMed ID: 16397235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of vascular endothelial growth factor-induced angiogenesis by scopoletin through interrupting the autophosphorylation of VEGF receptor 2 and its downstream signaling pathways.
    Pan R; Dai Y; Gao XH; Lu D; Xia YF
    Vascul Pharmacol; 2011; 54(1-2):18-28. PubMed ID: 21078410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis.
    Scharpfenecker M; van Dinther M; Liu Z; van Bezooijen RL; Zhao Q; Pukac L; Löwik CW; ten Dijke P
    J Cell Sci; 2007 Mar; 120(Pt 6):964-72. PubMed ID: 17311849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.